Quick Answer
GOLDENWELL BIOTECH, INC. reported Stockholders Equity of -$47.2 thousand for the year ending 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -156.1% in Stockholders Equity from 2023 to 2024.
- This data is from GOLDENWELL BIOTECH, INC.'s annual report (Form 10-K), filed with the SEC on May 15, 2025.
- XBRL data for this metric is available from 2019 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $0.00 | Q4 2019: $246.6 thousand | Q1 2020: $251.6 thousand | Q2 2020: $251.4 thousand | Q3 2020: $250.5 thousand | Q1 2021: $372.6 thousand | Q2 2021: $349.0 thousand | Q3 2021: $331.3 thousand | Q1 2022: $268.3 thousand | Q2 2022: $241.5 thousand | Q3 2022: $237.0 thousand | Q1 2023: $168.0 thousand | Q2 2023: $140.9 thousand | Q3 2023: $105.5 thousand | Q4 2023: $84.7 thousand | Q1 2024: $53.7 thousand | Q2 2024: $3.8 thousand | Q3 2024: $19.2 thousand | Q4 2024: -$47.2 thousand | Q1 2025: -$81.6 thousand | Q2 2025: -$86.8 thousand | Q3 2025: -$94.8 thousand.
- Over the full 15 years of available data (2019 to 2024), GOLDENWELL BIOTECH, INC.'s Stockholders Equity has declined by 119.2%.
- Historical annual values: Fiscal year 2024: -$47.2 thousand | Fiscal year 2023: $84.3 thousand | Fiscal year 2023: $105.5 thousand | Fiscal year 2023: $140.9 thousand | Fiscal year 2023: $168.0 thousand | Fiscal year 2022: $201.6 thousand | Fiscal year 2022: $237.0 thousand | Fiscal year 2022: $241.5 thousand | Fiscal year 2022: $268.3 thousand | Fiscal year 2021: $301.7 thousand | Fiscal year 2021: $331.3 thousand | Fiscal year 2021: $349.0 thousand | Fiscal year 2021: $372.6 thousand | Fiscal year 2020: $248.6 thousand | Fiscal year 2019: $246.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: